期刊文献+

前列腺癌治疗性DNA疫苗的研究进展

Research progress of therapeutic DNA vaccines for prostate cancer
下载PDF
导出
摘要 治疗性DNA疫苗是前列腺癌免疫治疗的新途径之一,本文主要介绍了以前列腺癌相关抗原PSA、PAP、PSMA、PSCA、STEAP等为靶点的DNA疫苗的研究现状,分析了DNA疫苗在前列腺癌免疫治疗领域的发展趋势及前景。 DNA vaccine is a new approach of immunotherapy for prostate cancer. This review provides a detailed look at the attributes and immunologic mechanisms of DNA vaccines encoding prostate cancer tissuespecific target antigens (PSA, PAP, PSMA, STEAP and PSCA) and their utility as well as potential prospects in prostate cancer immunotherapy.
出处 《免疫学杂志》 CAS CSCD 北大核心 2013年第6期540-545,共6页 Immunological Journal
基金 国家自然科学基金项目(30840094)
关键词 前列腺癌 免疫治疗 DNA疫苗 肿瘤抗原 Prostate cancer Immunotherapy DNA vaccines Tumor antigens
  • 相关文献

参考文献33

  • 1Sonpavde G, Agarwal N, Choueiri TK, et al. Recent advances in immunotherapy for the treatment of prostate Cancer[J]. Expert Opin Biol Ther, 2011, 11(8): 997-1009.
  • 2Hall SJ, Klotz L, Pantuck AJ, et al. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer[J]. J Urol, 2011, 186(3): 877- 881.
  • 3Buonerba C, Ferro M, Di Lorenzo G. Sipuleucel-T for prostate cancer, the immunotherapy era has commenced[J]. Expert Rev Anticancer Ther, 2011, 11(1): 25-28.
  • 4Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery systems for cancer therapy [J]. Mol Cancer, 2011, 10: 3.
  • 5Liu MA. DNA vaccines: an historical perspective and view to the future[J]. Immunol Rev, 2011,239(1): 62-84.
  • 6Signori E, Iurescia S, Massi E, et al. DNA vaccination strategies for anti-tumour effective gene therapy protocols[J]. Cancer Immunol Immunother, 2010, 59(10): 1583-1591.
  • 7Alam S, Douglas GM. DNA vaccines for the treatment of prostate cancer[J]. Expert Rev Vaccines, 2010, 9(7): 731-745.
  • 8Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase Ⅱ randomized controlled trial of Poxviral -based PSA -targeted imnmnotherapy in metastatic castration-resistant prostate cancer [J]. J Clin Oncol, 2010, 28(7): 1099-1105.
  • 9Gulley JL Aden PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer [J]. Cancer Immunol Immunother, 2010, 59(5): 663-674.
  • 10Kim JJ, Trivedi NN, Wilson DM, et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine[J]. Oncogene, 1998, 17(24): 3125-5135.

二级参考文献12

  • 1张克勤,聂志林,梁培禾,孙中义,李彦锋,靳凤烁.人PSCA基因真核载体的构建与表达[J].免疫学杂志,2009,25(3):307-310. 被引量:2
  • 2Madan RA, Mohebtash M, Schlom J, et al. Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinicaltrial design [J]. Expert Opin Biol Ther, 2010, 10(1): 19-28.
  • 3Madan RA, Pal SK, Sartor 0, et al. Overcoming chemotherapy resistance in prostate cancer [J]. Clin Cancer Res, 2011, 17(12): 3892-3902.
  • 4Madan RA, Gulley JL. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer [J]. Expert Rev Vaccines, 2011, 10(2): 141-150.
  • 5Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010, 363(5): 411-422.
  • 6Zarour L, A|umkal J. Emerging therapies in castrate- resistant prostate cancer [J].Curr Urol Rep, 2010, 11 (5): 152-158.
  • 7Matera L. The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer [J]. Cancer Treat Rev, 2010, 36(2): 131-141.
  • 8Jahnisch H, F ii ssel S, Kiessling A, et al. Dendritic cell-based immunotherapy for prostate cancer [J]. Clin Dev Immunol, 2010, 14(2): 287-292.
  • 9Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances,lessons learned,and areas for further research[J]. Clin Cancer Res, 2011, 17(12): 3884-3891.
  • 10Sipuleucel-t GP. In metastatic castration-resistant prostale cancer[J]. Drugs, 2011, 71(1): 101-108.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部